Home > Gastroenterology > ECCO 2022 > Novel Treatment Modalities > Upadacitinib counters extraintestinal manifestations in ulcerative colitis

Upadacitinib counters extraintestinal manifestations in ulcerative colitis

Presented By
Prof. Jean-Frédéric Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2022
Trial
Phase 3, U-ACHIEVE; U-ACCOMPLISH
Upadacitinib was more effective than placebo in resolving extraintestinal manifestations (EIMs) in participants with ulcerative colitis (UC) in a phase 3 trial. Induction therapy with upadacitinib initiated the resolution of EIMs, whereas maintenance therapy elicited further improvements. A higher maintenance dose was associated with greater gains than a lower maintenance dose. EIMs are frequently observed in patients with UC. In addition, these EIMs are challenging to treat and may reduce the quality of life for patients with UC. Since the JAK inhibitor upadacitinib was demonstrated to be safe and efficacious in patients with UC, Prof. Jean-Frédéric Colombel (Icahn School of Medicine at Mount Sinai, NY, USA) aimed to evaluate the impact of upadacitinib on EIMs in participants with moderately to severely active UC [1–4]. Data was included from the phase 3 U-ACHIEVE induction and maintenance trials (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on